Pharmacoeconomic analysis of micafungin (mycamine) 100 mg and 150 mg daily in the treatment of candidemia

P and T

Volumn 34, Issue 4, 2009, Pages 196-199

  Marfo, Kwaku ^a   Guo, Yi ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Candidemia; Micafungin; Pharmacoeconomics

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; APACHE; ARTICLE; BLOOD CULTURE; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CATHETER; CONTROLLED STUDY; CORRELATION COEFFICIENT; COST MINIMIZATION ANALYSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG COST; DRUG TOLERABILITY; FEMALE; FUNGUS ISOLATION; HEMODIALYSIS; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; MYCOLOGY; OUTCOME ASSESSMENT; PHARMACOECONOMICS; RETROSPECTIVE STUDY; RISK FACTOR; STUDENT T TEST; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 66949117066     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Wisplinghoff H, Bidchoff T, Tallent SM. National nosocomial bloodstream infections in U. S. hospitals: Analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:307-317.
2. Trick WE, Fridkin SK, Edwards JR. Secular trend of hospitalacquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-630.
3. Gudlaugsson O, Gillespie S, Lee K. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:1172-1177.
4. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M. Micafungin versus liposomal amphotericin B for candidemia and invasive candidosis: A phase II randomized double-blind trial. Lancet 2007; 369 (9572): 1519-1527.
5. Pfaller MA, Diekema DJ, for the International Fungal Surveillance Group. Twelve years of fluconazole in clinical practice: Global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10 (Suppl 1): 11-23.
6. deWet NT, Bester AJ, Viljoen JJ. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21:899-907.
7. Wiederhold NP, Lewis RE. The echinocandin antifungals: An overview of the pharmacology, spectrum, and clinical efficacy. Exp Opin Invest Drugs 2003;12:1313-1333.
8. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, non-comparative, clinical trial of micafungin alone and in combination for the treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24:654-661.
9. Pappas PG, Rotstein CMF, Betts RE Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45 (7): 883-893.
10. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998;27 (4): 781-788.